Atopic Dermatitis Not Responding to Topical Corticosteroid or Calcineurin Inhibitor — What to Do Next

This protocol addresses localized atopic dermatitis (AD) lesions that remain uncontrolled despite a first-line topical regimen, and defines the next clinical step when the expected response has not been achieved.

Prior therapy that did not achieve its goal

The previous treatment — a topical corticosteroid or a topical calcineurin inhibitor (pimecrolimus or tacrolimus) — was expected to produce measurable improvement within 2 to 6 weeks. When that response is not achieved, this protocol applies.

Next-line approach (partial overview)

The next step uses an occlusive technique — applying a topical corticosteroid under wet (damp) clothing or dressings — deployed in a time- and body-area-limited fashion. The full regimen, patient selection criteria, and application specifics are in the complete protocol.

Clinical goal: Rapid resolution of localized atopic dermatitis lesions that have been refractory to standard topical treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.anai.2023.11.009

In patients with localized uncontrolled atopic dermatitis refractory to mid-high−potency topical treatment (US classes 2–5 or tacrolimus), the JTF panel suggests addition of a time and body area-limited (eg, 4–7 days; minimum 1 hour to maximum overnight, once per day) trial of occlusive low-mid−potency topical corticosteroid (US classes 3–7) therapy over continued standard topical therapy alone (conditional recommendation, very low-certainty evidence).

Experiential evidence from patients and clinicians suggested that, when used judiciously for specific, local treatment of lesions in a time-limited fashion, most patients experience rapid resolution of AD lesions refractory to corresponding topical treatment without temporary occlusion.

View source ↗